• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Rixubis (Coagulation Factor IX (Recombinant)]

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Rixubis (Coagulation Factor IX (Recombinant)]

  • Profile

Profile

Contact Information

Contact: Takeda Pharmaceutical Company
Website: http://www.rixubis.com/

Currently Enrolling Trials

    Show More

    General Information

    Rixubis (Coagulation Factor IX [Recombinant]) is a recombinant factor IX (rFIX) protein.

    Rixubis is specifically indicated for the control and prevention of bleeding episodes, perioperative management and routine prophylaxis to prevent or prevent or reduce the frequency of bleeding episodes in adults with hemophilia B.

    Mechanism of Action

    Rixubis is a recombinant factor IX (rFIX) protein.

    Side Effects

    Adverse events associated with the use of Rixubis may include, but are not limited to, the following:

    • dysgeusia
    • pain in extremity
    • positive test for furin antibody

    Dosing/Administration

    Rixubis is supplied as a powder for reconstitution into a solution for intravenous infusion. The initial recommended dose is based on the following formula: initial dose = body weight (kg) x desired factor IX increase (% or IU/dL) x reciprocal of observed recovery (IU/dL per IU/kg). The dose for previously treated patients is 40 to 60 international units per kg twice weekly. Titration of dose may be necessary depending upon the individual patient’s age, bleeding pattern and physical activity.

    Clinical Trial Results

    The FDA approval of Rixubis was based on a phase 1/3 prospective, open-label, uncontrolled, multicenter study that investigated the pharmacokinetics, efficacy and safety of Rixubis in 73 previously-treated patients (between 12 and 65 years of age) with severe (factor IX level <1 percent) or moderately severe (factor IX level =2 percent) hemophilia B. Subjects received Rixubis either for prophylaxis and/or for the treatment of bleeding episodes on an on-demand basis and were exposed to a factor IX-containing product on >50 days. Fifty-nine subjects received Rixubis for prophylaxis twice-weekly and 56 of them received treatment for a minimum of three months. An additional 14 subjects received Rixubis for the treatment of bleeding episodes only and had to have at least 12 documented bleeding episodes requiring treatment within 12 months prior to enrollment. Twice-weekly prophylactic treatment with Rixubis for six months achieved a median annualized bleed rate (ABR) of 2.0 with 43 percent of subjects experiencing no bleeds. In this study, no subjects developed an inhibitory antibody to FIX and no cases of anaphylaxis were reported.

    Approval Date: 2013-06-01
    Company Name: Baxter International
    Back to Listings

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing